Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced tumor immunity in a subset of patients. We studied...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Patrick, Dillon, Richard, Radia, Deepti, Rousselot, Philippe, McLornan, Donal P., Ong, Mark, Green, Anna, Verde, Alessandro, Hussain, Farzana, Raj, Kavita, Kordasti, Shahram, Harrison, Claire, de Lavallade, Hugues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Chronic Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230408/
https://www.ncbi.nlm.nih.gov/pubmed/36700403
http://dx.doi.org/10.3324/haematol.2022.282005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230408/
https://www.ncbi.nlm.nih.gov/pubmed/36700403
http://dx.doi.org/10.3324/haematol.2022.282005

Ejemplares similares